Clinical trial
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease…
NCT00256204 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00256204 |
|---|---|
| Title | A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease |
| Official title | A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects |
| Acronym | ADAGIO |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug, Other |
| Interventions | Rasagiline Mesylate, Placebo |
| Enrollment | 1,174 |
| Start date | Nov 1, 2005 |
| Primary completion | Apr 1, 2008 |
| Completion | Jun 1, 2009 |
| First posted | Nov 21, 2005 |
| Last update posted | Jan 12, 2012 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: